Description: Developing cause-oriented treatment for Parkinson's, Alzheimer's, and Lou Gehrig's diseases based on preventing mitochondrial DNA damage, the earliest recognized event in these neurodegenerative disorders, with proprietary polyamine drug, Tetramine.